NASDAQ:KRYS

Krystal Biotech Near Highs After Insider Filing Ahead of 2026 Data
····

Krystal Biotech Near Highs After Insider Filing Ahead of 2026 Data

Krystal Biotech EVP Thomas John Charles sold 642 shares at $302.03 each on May 26, leaving him with no directly held common stock, according to an SEC filing. KRYS traded at $306.63, near its 52-week high, with the company valued around $9.35 billion. VYJUVEK, Krystal’s gene therapy for DEB, posted Q1 revenue of $116.4 million. Two late-stage readouts are expected this year.
May 28, 2026

Stock Market Today

  • Atlas Arteria Rejects IFM Takeover Offer Citing Undervaluation
    June 1, 2026, 8:46 PM EDT. Atlas Arteria Group (ASX: ALX) has formally rejected the $4.75 per security takeover bid from IFM Investors, with independent directors stating the offer undervalues the company. The Independent Expert's Report values the shares between $5.39 and $6.20, above IFM's offer and Atlas Arteria's recent closing price of $5.04 (June 1, 2026). The board criticized the deal as "too low, opportunistic and highly conditional," warning shareholders that accepting now may preclude selling at higher market prices during the potential 12-month offer period. IFM retains the right to raise its offer up to $5.10 within 12 months post-offer close. Atlas Arteria will continue shareholder engagement and focus on long-term value from its toll road assets in France, Germany, and the U.S.